在帕金森病中的草药干预:临床前研究的系统审查
Wanlin Zhao1, Hailiang Cui1, Jihong Liu1
1Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan Province, China.
Cellular and molecular neurobiology
|May 23, 2025
概括
来自传统中医药 (TCM) 的天然化合物显示出治疗帕金森病 (PD) 的前景. 本综述强调了TCM对PD机制的神经保护的潜在多目标疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 帕金森病 (PD) 是一种流行的神经退行性疾病,影响多巴胺基神经元.
- 随着PD发病率的上升,需要新的多目标治疗策略.
- 现有的审查往往限制了PD自然产品研究中的单个机制或化合物的范围.
研究的目的:
- 系统地评估对帕金森病 (PD) 传统中医 (TCM) 的临床前研究.
- 评估32种生物活性成分和10种TCM PD配方的治疗潜力.
- 探索TCM在关键PD致病机制中的疗效.
主要方法:
- 2018年至2025年间发表的临床前研究的系统审查.
- 对32种生物活性成分和10种类型的TCM配方进行分析.
- 检查包括氧化应激,铁,神经炎症,肠道微生物群,线粒体功能障碍,自和ER应激等机制.
主要成果:
- 确定了32种生物活性成分和10种TCM配方,具有PD的治疗潜力.
- 证明了TCM在准多个PD相关途径方面的有效性.
- 突出了TCM在解决氧化应激,铁,神经炎症和其他关键机制方面的作用.
结论:
- TCM活性成分为帕金森病提供了有前途的多目标治疗途径.
- 本综述为开发下一代植物性PD药物提供了跨学科的基础.
- 结合TCM见解的进一步研究可以推进帕金森病的治疗策略.
相关概念视频
01:24Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:37Neural Regulation
43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
190
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
190